Scientists test reproductive safety of SMA gene therapy in mice

'Thorough risk assessment' urged for patients considering pregnancy

Written by Andrea Lobo |

A mouse is seen peeking out from around a corner.

In a preclinical study using mice, onasemnogene abeparvovec, sold as Zolgensma and Itvisma, did not cause reproductive harm. (Image from iStock)

  • In a mouse study, scientists found that the SMA gene therapy agent onasemnogene abeparvovec is safe for patients of reproductive age.
  • The drug is the main ingredient in the approved treatments Zolgensma and Itvisma, both sold by Novartis, which funded the research.
  • The results showed negligible risk, with no notable issues found regarding reproductive cells, fertility, or embryonic and fetal development.

In a new study using mice, onasemnogene abeparvovec, sold as Zolgensma and Itvisma — two approved gene therapies for spinal muscular atrophy (SMA) — did not cause notable issues in reproductive cells, fertility, or embryonic development.

Indeed, the preclinical study found no evidence of reproductive harm due to the gene therapy agent. According to the researchers, the findings suggest that use of this medication poses a very low risk of being passed on to offspring through reproductive cells, “supporting its safe use in populations with reproductive potential.”

“These nonclinical findings indicate that [onasemnogene abeparvovec] administration … at clinically relevant doses poses a negligible risk,” the team wrote, noting the results “[provide] a clinically relevant assessment of reproductive and developmental safety.”

Still, the scientists concluded that, “due to limited long-term human data, pregnant individuals or those considering pregnancy should have a thorough risk assessment before receiving [gene therapy].”

The study, “Reproductive safety and germline transmission risk of onasemnogene abeparvovec following i.v. or i.c.v. administration in mice,” was published in the journal Molecular Therapy Advances. It was funded by Novartis, the company that markets both Zolgensma and Itvisma. All nine study authors work for the drug developer.

Recommended Reading
The acronym MDA is seen among strands of DNA.

MDA 2026: Itvisma, Zolgensma show extended safety, efficacy in SMA

A rare disease, SMA is chiefly caused by mutations in both copies of the SMN1 gene, which results in insufficient levels of the survival motor neuron (SMN) protein. SMN is essential for the health of motor neurons, the nerve cells that control muscle movement.

Onasemnogene abeparvovec uses a genetically engineered and harmless adeno-associated virus to deliver a functional version of SMN1 to the body’s cells. Zolgensma is given via an intravenous, or into-the-vein, infusion into the bloodstream, while Itvisma is administered into the fluid surrounding the spinal cord.

Both gene therapies can stay in the body for a long time after a single administration — one of the reasons why they are effective in treating SMA. However, given that, the researchers questioned whether the viral vector reaches reproductive organs and if it could affect fertility, pregnancy, or the health of offspring.

No reproductive harm seen with SMA gene therapy

Now, the Novartis team addressed these questions in mice. First, newborn mice received a single intravenous dose of the treatment. The scientists detected the viral vector’s genetic material in testes and ovaries, but at substantially lower levels than in organs such as the liver, heart, and skeletal muscles. No treatment-related changes were found in the structure or weight of reproductive organs, according to the researchers.

In a separate study, newborn mice received the gene therapy either intravenously or via an injection into the brain’s fluid-filled spaces. Although the vector’s DNA was detected in reproductive organs — including the ovaries and testes — in some mice, the researchers found no evidence of it in sperm cells or oocytes, which are immature egg cells.

“Together, these data suggest that the risk of clinically significant … transmission in humans following AAV gene therapy is considered very low, though not zero,” the researchers wrote.

In further experiments, adult mice received one of two doses of onasemnogene abeparvovec before mating. The team noted that the highest dose used was equivalent to the approved intravenous dose. Treatment did not affect mating, fertility, or early embryonic development, the data showed. In females, the highest dose was associated with slightly longer reproductive cycles, but this did not affect fertility or the ability to produce offspring, according to the researchers.

Importantly, the absence of adverse effects on fertility, [and] embryofetal development, … supports the safety of [SMA gene therapy] for patients of reproductive age.

The team also assessed female mice receiving the treatment during early pregnancy. Gene therapy did not affect maternal health, fetal weight, or the development of fetal organs and bones. Although the vector’s DNA was detected in maternal tissues, including the placenta, it was not detected in fetal tissues, the researchers noted.

“Importantly, the absence of adverse effects on fertility, embryofetal development, and transplacental transfer [transfer from the mother to the fetus through the placenta] — even at doses exceeding those used clinically — supports the safety of [the gene therapy] for patients of reproductive age,” the scientists wrote.

However, given that these studies involved rodents and not people, the team recommended that any humans considering SMA gene therapy who may wish to have a baby undertake a comprehensive review of the potential risks.

“These findings are integral for informing clinical risk assessments, regulatory submissions, and product labeling, ensuring that patients and health care providers can make informed decisions about gene therapy with confidence in its reproductive safety,” the team wrote.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.